1. Lactobacillus fermentum attenuates the alveolar bone loss in ligature-induced periodontitis in mice.
- Author
-
Lee Y, Jung BH, Yoo KY, Lim HJ, Shin KJ, and Lee JK
- Subjects
- Animals, Mice, Probiotics therapeutic use, Male, Cytokines metabolism, Random Allocation, Ligation, Alveolar Bone Loss diagnostic imaging, Alveolar Bone Loss prevention & control, Alveolar Bone Loss microbiology, Limosilactobacillus fermentum, Periodontitis therapy, Periodontitis microbiology, Periodontitis pathology
- Abstract
Objective: This study investigated the effects of Lactobacillus fermentum BELF11 on periodontitis in mice (LIP)., Methods: Sixty mice were randomly assigned to a control group (CTL), LIP/PBS group (LIP and PBS applied), or LIP/BELF11 group (LIP and L. fermentum BELF11 applied). For 14 days, PBS or L. fermentum BELF11 was applied twice daily to the mice in the LIP/PBS or LIP/BELF11 group, respectively. After 14 days, radiographic, histological, and pro-inflammatory cytokine assessments were conducted., Results: The LIP/PBS and LIP/BELF11 groups demonstrated greater alveolar bone loss than the CTL group (p < 0.05). The LIP/BELF11 group showed significantly reduced alveolar bone loss on the mesial side compared to the LIP/PBS group. Histologically, the LIP/BELF11 group showed consistent patterns of connective tissue fiber arrangement, lower levels of inflammatory infiltration, less alveolar bone loss, and higher alveolar bone density than the LIP/PBS group, despite showing more signs of destruction than the CTL group. The LIP/BELF11 group also exhibited significantly lower levels of pro-inflammatory cytokines than the LIP/PBS group., Conclusions: L. fermentum BELF11 inhibits alveolar bone loss and periodontitis progression by regulating pro-inflammatory cytokine production. These findings suggest that L. fermentum BELF11 may be a potential adjunctive therapy in periodontal treatment., (© 2023 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF